Cilastatin protection against cyclosporin A-induced nephrotoxicity: Clinical evidence

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 505-513

  Tejedor, Alberto ^a   Torres, A M ^a   Castilla, M ^a   Lazaro, J A ^a   De Lucas, C ^a   Caramelo, C ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Jimenez Diaz Foundation   (Spain)

Author keywords

Cilastatin; Cyclosporin A; Meta analysis; Nephrotoxicity

Indexed keywords

AZATHIOPRINE; CILASTATIN; CILASTATIN PLUS IMIPENEM; CREATININE; CYCLOSPORIN A;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 33947400546     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167633     Document Type: Article

References (27)

1. English J, Evan A, Houghton DC, et al. Cyclosporin-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987;44:135-41
2. Grimbert P, Baron C, Fruchaud G, et al. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CyA, in low-risk renal transplant recipients. Transplant Int 2002;15:550-5
3. De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000;35:333-46
4. Rao KV. Diagnosis of renal transplant rejection in the cyclosporine era. Curr Opin Nephrol Hypertens 1992;1: 280-90
5. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994;58: 170-8
6. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997;63:664-8
7. Sido B, Hammer C, Mraz W, et al. Nephroprotective effect of imipenem/cilastatin in reducing cyclosporine toxicity. Transplant Proc 1987;1:1755-8
8. Kahan FM, Kropp H, Sundelof JG, et al. Thienamycin: development of imipenem-cilastatin. J Antimicrob Chemother 1983;12:1-35
9. Hammer C, Thies JC, Mraz W, et al. Reduction of cyclosporin (CyA) nephrotoxicity by imipenem/cilastatin after kidney transplantation in rats. Transplant Proc 1989;21:931
10. Markewitz A, Hammer C, Pfeiffer M, et al. Reduction of cyclosporin-induced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation 1994;57:865-70
11. Carmellini M, Frosini F, Filipponi F, et al. Effect of cilastatin on cyclosporine-induced acute nephrotoxicity in kidney transplant recipients. Transplantation 1997;64:164-6
12. Carmellini M, Matteucci E, Boggi U, et al. Imipenem/cilastatin reduces cyclosporin-induced tubular damage in kidney transplant recipients. Transplant Proc 1998;30:2034-5
13. Baghaie A, Bayat M, Abobo C, et al. The effect of imipenem/ cilastatin on acute cyclosporine nephrotoxicity in heart/lung transplant patients. Crit Care Med 1995;23:A241
14. Gruss E, Tomas JF, Bernis C, et al. Nephroprotective effect of cilastatin in allogeneic bone marrow transplantation. Results from a retrospective analysis. Bone Marrow Transplant 1996;18:761-5
15. Nakamura T, Kokuryo T, Hashimoto Y, et al. Effects of fosfomycin and imipenem/cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats. J Pharm Pharmacol 1999;51:227-32
16. Toyoguchi T, Takahashi S, Hosoya J, et al. Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob Agents Chemother 1997;41:1985-90
17. Pérez M, Castilla M, Torres AM, et al. Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. Nephrol Dial Transplant 2004;19:2445-55
18. Parkin ET, Turner AJ, Hooper NM. Differential effects of glycosphingolipids on the detergent insolubility of the glycosylphosphatidylinositol-anchored membrane dipeptidase. Biochem J 2001;358:209-16
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48
20. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of randomized trials. Prog Cardiovasc Dis 1985;27:335-71
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
22. Berlin JA, Laird NM, Sacks HS, et al. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989;8:141-51
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
24. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889-94
25. Hortelano S, Castilla M, Torres AM, et al. Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells. J Am Soc Nephrol. 2000;11:2315-23
26. Sack K, Herhahn J, Marre R, et al. Renal tolerance of imipenem cilastatin and other beta-lactam antibiotics in rats. Infection 1985;13:S156-60
27. Yee GC. Pharmacokinetic interactions between cyclosporine and other drugs. Transplant Proc 1990;22:1203-07